Ciliary neurotrophic factor for macular telangiectasia type 2: results from a phase 1 safety trial
about
Neuroprotection, Growth Factors and BDNF-TrkB Signalling in Retinal DegenerationLong-Term Safety of Transplanting Human Bone Marrow Stromal Cells into the Extravascular Spaces of the Choroid of Rabbits.CORRELATION OF STRUCTURAL AND FUNCTIONAL OUTCOME MEASURES IN A PHASE ONE TRIAL OF CILIARY NEUROTROPHIC FACTOR IN TYPE 2 IDIOPATHIC MACULAR TELANGIECTASIA.CNTF Attenuates Vasoproliferative Changes Through Upregulation of SOCS3 in a Mouse-Model of Oxygen-Induced Retinopathy.The Pathway From Genes to Gene Therapy in Glaucoma: A Review of Possibilities for Using Genes as Glaucoma Drugs.Current advances in the treatment of neovascular age-related macular degeneration.Delivery of therapeutics to posterior eye segment: cell-encapsulating systemsWhen is macular edema not macular edema? An update on macular telangiectasia type 2.Correlation Between Macular Integrity Assessment and Optical Coherence Tomography Imaging of Ellipsoid Zone in Macular Telangiectasia Type 2.Nondamaging Retinal Laser Therapy: Rationale and Applications to the Macula.Global Connections to Study Idiopathic Macular Telangiectasia Type 2.Ciliary neurotrophic factor (CNTF) delivery to retina: an overview of current research advancements.Quantitative analysis of photoreceptor layer reflectivity on en-face optical coherence tomography as an estimator of cone density.A Novel Neuroprotective Small Molecule for Glial Cell Derived Neurotrophic Factor Induction and Photoreceptor Rescue.Photoreceptor Protection by Mesencephalic Astrocyte-Derived Neurotrophic Factor (MANF).Encapsulated Cell Technology-Based Delivery of a Complement Inhibitor Reduces Choroidal Neovascularization in a Mouse Model.Stem Cells, Bioengineering, and 3-D Scaffolds for Nervous System Repair and Regeneration
P2860
Q28069477-DA04B164-7EA2-46FA-9325-DCB63B9A84CCQ33862445-286B1375-D6F9-4A60-A3BE-DA096DE96A7FQ36379980-0C328DF5-31BC-4DF8-8682-7E685BC77D5DQ37179640-F615D146-877A-4AFA-8C9C-2C5108526B32Q38761425-A9BD9E3A-59E9-4EAB-98EC-A0FF7A3B83E8Q38902191-6512CFBB-C64D-4766-9DEB-09BDFA4C9A46Q41994586-2C82D30A-6C22-4AEC-8DBF-FFE17B125B1CQ42359936-5DD5351D-D092-4C4D-ABBE-CF73098273C7Q45163071-14ADAA34-1B63-4827-A11F-B2CD88B8BBCAQ46204149-3FE955AD-CC5F-4AD9-8E0C-2694C57E761CQ46566601-883B074A-8FD8-4CEE-A057-8426B8FA9129Q47601916-F29D0295-9C01-4D2B-B7E9-1ECB1BD5A428Q47815942-C4CB4305-25A4-4DD1-9F93-DBAAD5318CC6Q50653055-3CE99EDF-6023-4298-94CB-7A3F2333EA99Q52568117-690899AA-56C7-47CC-B926-36171BAC299DQ52724247-3FA0DA12-46BA-4D76-B284-FB0A4DEE74B4Q57345687-75872CBC-F355-4378-99C7-FA1388DC732C
P2860
Ciliary neurotrophic factor for macular telangiectasia type 2: results from a phase 1 safety trial
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Ciliary neurotrophic factor fo ...... ts from a phase 1 safety trial
@ast
Ciliary neurotrophic factor fo ...... ts from a phase 1 safety trial
@en
Ciliary neurotrophic factor fo ...... ts from a phase 1 safety trial
@nl
type
label
Ciliary neurotrophic factor fo ...... ts from a phase 1 safety trial
@ast
Ciliary neurotrophic factor fo ...... ts from a phase 1 safety trial
@en
Ciliary neurotrophic factor fo ...... ts from a phase 1 safety trial
@nl
prefLabel
Ciliary neurotrophic factor fo ...... ts from a phase 1 safety trial
@ast
Ciliary neurotrophic factor fo ...... ts from a phase 1 safety trial
@en
Ciliary neurotrophic factor fo ...... ts from a phase 1 safety trial
@nl
P2093
P2860
P1476
Ciliary neurotrophic factor fo ...... ts from a phase 1 safety trial
@en
P2093
Alan C Bird
Avner Ingerman
Ferenc B Sallo
Lawrence Singerman
MacTel-CNTF Research Group
Neal S Peachey
Steven D Schwartz
Traci E Clemons
P2860
P304
659-666.e1
P356
10.1016/J.AJO.2014.12.013
P407
P577
2014-12-19T00:00:00Z